Abstract: The present disclosure provides compositions and methods for genomic engineering.

Abstract: Provided herein are methods of identifying the origin of a nucleic acid sample. The methods include forming a reaction mixture comprising a nucleic acid sample comprising nucleic acid molecules from a single cell and a set of barcodes, incorporating the set of barcodes into the nucleic acid molecules of the sample, and identifying the set of barcodes incorporated into the nucleic acid molecules of the single cell thereby identifying the origin of the nucleic acid sample.

Abstract: Methods of amplification, purification and detection of nucleic acid sequences especially RNA are described. One aspect of the method involves the hybridisation and subsequent ligation of a nucleic acid structure to the nucleic acid sequence desired to be manipulated. The methods require that the nucleic acid structure comprises a double stranded region and a single stranded region. The single stranded region is complementary to the RNA sequence of interest. The double stranded region may also contain additional functionalities which are then used subsequently in the method.

Abstract: Disclosed are methods for trapping and barcoding discrete biological units in a hydrogel. Also disclosed are methods for analyzing gene expression, genotype, haplotype or epigenome in discrete biological units, as well as kits for implementing the methods of the present disclosure.

Abstract: The present disclosure provides methods for inhibiting and/or reducing self-reactive IgE and/or basophils, thereby treating or preventing lupus, lupus nephritis, and lupus-related disorders.

Abstract: This invention relates to polycomb-associated RNAs, libraries and fragments of those RNAs, inhibitory nucleic acids and methods and compositions for targeting RNAs, and methods of use thereof.

Abstract: Methods of the invention encompass delivery of nucleic acid sequences encoding ABCD1 for the treatment of X-linked Adrenoleukodystrophy (X-ALD), e.g., for Adrenomyeloneuropathy (AMN).

Abstract: Described herein are methods of treating a subject in need of treatment for liver fibrosis by administering a therapeutically effective amount of an inhibitor of high mobility box 2 gene (HMGB2). In an aspect, a composition comprises an inflachromene analog and a micro RNA or an interfering RNA that inhibits the expression of HMGB2. Also described is a composition including an anionic or cationic liposome particle, containing Vitamin A, and an inhibitor of HMGB2.

Abstract: The present invention relates to a stem cell having an immunosuppressive ability in which the expression or activity of a suppressor of cytokine signaling (SOCS) is inhibited, and a pharmaceutical composition for inhibiting immunity, which includes the stem cell. In addition, the present invention relates to a composition for inducing the immunosuppressive activity of a stem cell, including a suppressor of cytokine signaling (SOCS) expression or activity inhibitor. The inhibition of suppressor of cytokine signaling (SOCS) expression or activity, according to the present invention, may enhance the immunosuppressive ability of a stem cell, and the stem cell with enhanced immunosuppressive ability may be used as an effective cell therapeutic agent in an autoimmune disease, rejection upon organ transplantation, or an allergic disease.

Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of pathogens through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in pathogens. The disclosure also concerns methods for applying dsRNA through formulations and/or transgenic plants that express nucleic acid molecules useful for the control of pathogens, and the plant cells and plants obtained thereby.

Abstract: This invention is directed to an RNA interference (RNAi) agent and the use of that RNAi agent to treat Age-related Macular Degeneration, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agent is a DNA-directed RNA interference (ddRNAi) agent (being an RNA molecule), together with an expression cassette or construct to express that agent in a cell (including in vivo), for inhibiting, preventing or reducing expression of an AMD associated gene. Preferably that AMD associated gene is one that is associated with wet AMD.

Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.

Abstract: The present invention provides functional aptamer-comprising tRNA molecules, useful in the study of tRNA and ribosomal activity.

Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.

Abstract: Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.

Abstract: A method is provided for site-specific insertion of foreign DNA into a genome in an animal cell, including (1) a step of constructing a donor plasmid in which DNA of 100 bp to 300 bp having a sequence homologous to an insertion site on a genome is ligated to the upstream and downstream of foreign DNA of 0.1 kbp to 10 kbp, and (2) a step of inserting the foreign DNA of 0.1 kbp to 10 kbp into a target site on the genome by a homology-directed repair-based genome editing method using the obtained donor plasmid.

Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.

Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).

Abstract: The invention relates to compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

Abstract: Provided herein include methods and compositions for effecting a targeted genetic change in DNA in a cell. Certain aspects and embodiments relate to improving the efficiency of the targeting of modifications to specific locations in genomic or other nucleotide sequences. As described herein, nucleic acids which direct specific changes to the genome may be combined with various approaches to enhance the availability of components of the natural repair systems present in the cells being targeted for modification.

Abstract: The present invention relates to a plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, wherein the plant has a reduced level, reduced activity or complete absence of DMR6 protein as compared to a plant that is not resistant to the said pathogen, in particular organisms of the Fungi or the phylum Oomycota. The invention further relates to a method for obtaining a plant, which is resistant to a pathogen of viral, bacterial, fungal or oomycete origin, comprising reducing the endogenous level or activity of DMR6 protein in the plant. In addition, the invention relates to the use of a DMR6 promotor for providing disease resistant plants.

Abstract: The present invention relates to a method of improving stress tolerance and/or preventing growth reduction of a plant by introducing a polynucleotide encoding a Repetitive Proline-rich Protein (RePRP) into the plant.

Abstract: Methods of increasing the resistance of a crop plant to heat stress and in particular methods of improving the grain yield and quality of crop plants grown under heat stress in the form of increased minimal temperatures are provided. The methods include selecting plants with increased expression of HYR and growing these plants in regions expected to experience minimal temperatures above 25° C. during the growing season. Methods of screening plants for increased resistance to heat stress and methods of producing grain in regions having minimal temperatures of 25° C. or more are also provided.

Abstract: The present invention provides for transgenic plants and methods of producing such transgenic plants, wherein the transgenic plants express an increased amounts of PYL9 to interact with abscisic acid (ABA) thereby activating enhanced drought resistance and leaf senescence relative to control or wild-type plants.

Abstract: Compositions and methods for enhancing the resistance of wheat and barley plants to wheat stripe rust caused by Puccinia striiformis f. sp. tritici are provided. The compositions comprise nucleic acid molecules encoding resistance (R) gene products and variants thereof and plants, seeds, and plant cells comprising such nucleic acid molecules. The methods for enhancing the resistance of wheat and barley plants to wheat stripe rust comprise introducing a nucleic acid molecule encoding an R gene product into a wheat or barley plant cell. Additionally provided are methods for using the wheat and barley plants in agriculture to limit wheat stripe rust.

Abstract: An in vitro method for integrating an exogenous DNA sequence into the genome of a cell using a transposon system. The transposon system includes a first vector carrying inverted repeat sequences and an exogenous DNA, and a second vector that expresses a transposases. Also provided is a kit including the transposon system for integrating an exogenous DNA into the genome of a cell. A method for treating a subject is described that includes engineering an immune cell to carry an exogenous DNA sequence using the method and/or the kit described above and administering an effective amount of the engineered immune cell to the subject.

Abstract: Disclosed herein are Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) 9-based system related compositions and methods of using said CRISPR/Cas9-based system related compositions for altering gene expression and genome engineering. Also disclosed herein are compositions and methods of using said compositions for altering gene expression and genome engineering in muscle, such as skeletal muscle and cardiac muscle.

Abstract: The present invention provides an integration-defective lentiviral vector based on a parental lentivirus and related methods, the integration-defective lentiviral vector including one or more of the following: (a) a mutation, deletion or other modification of one or more binding sites for a host factor involved in gene silencing; (b) an addition of one or more binding sites for a transcription activator, which can be natural (such as but not limited to ubiquitous and/or tissue/cell type specific) including but not limited to SP1 NFkB, or synthetic including but not limited to binding sites for tetracycline regulated trans activators tTA, rtTA, tT65, and/or rtT65; (c) one or more nucleic acid sequences from a SV40 genome, wherein the one or more sequences are obtained from a region of the SV40 genome upstream to the SV40 poly-adenylation signal; (d) a shRNA expression cassette, which encodes a shRNA directed to a host gene involved in epigenetic silencing and/or in DNA repair pathways; or (e) any combination o

Abstract: A method of using a virus-like particle from a polyomavirus having a first nucleic acid as a cargo to detect a second nucleic acid. The method includes providing the virus-like particle from the polyomavirus having the first nucleic acid as the cargo, and detecting, via the virus-like particle from the polyomavirus, the second nucleic acid.

Abstract: The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.

Abstract: This invention pertains to mutant Cas9 nucleic acids and proteins for use in CRISPR/Cas endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant Cas9 protein, wherein the isolated mutant Cas9 protein is active in a CRISPR/Cas endonuclease system, wherein the CRISPR/Cas endonuclease system displays reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system. The invention also includes isolated nucleic acids encoding mutant Cas9 proteins, ribonucleoprotein complexes and CRISPR/Cas endonuclease systems having mutant Cas9 proteins that display reduced off-target editing activity and maintained on-target editing activity relative to a wild-type CRISPR/Cas endonuclease system.

Abstract: The present disclosure provides a system for editing genomic DNA, the system comprising an asymmetric donor DNA template; and methods of editing genomic DNA involving use of an asymmetric donor DNA template. The present disclosure provides a system for editing genomic DNA, the system comprising a Cas9 polypeptide with reduced enzymatic activity; and methods of editing genomic DNA involving use of a Cas9 polypeptide with reduced enzymatic activity.

Abstract: The present disclosure relates to recombinant yeast host cells having (i) a first genetic modification for reducing the production of one or more native enzymes that function to produce glycerol or regulating glycerol synthesis and/or allowing the production of an heterologous glucoamylase and (ii) a second genetic modification for reducing the production of one or more native enzymes that function to produce trehalose or regulating trehalose synthesis and/or allowing the expression of an heterologous trehalase. The recombinant yeast host cells can be used to limit the production of (yeast-produced) trehalose (particularly extracellular trehalose) during fermentation and, in some embodiments, can increase the production of a fermentation product (such as, for example, ethanol).

Abstract: The invention relates to an Amycolatopsis strain derived from the Amycolatopsis Zyl 926 strain having at least one additional copy of the FCS and ECH genes encoding feruloyl-CoA-synthetase and enoyl-CoA-hydratase/aldolase integrated at the integration site of the ?C31 phage. The invention also relates to the method for producing such strains, the integration cassette of the FCS and ECH genes, the use of said strains in a method for producing vanillin, and a method for producing vanillin.

Abstract: This document describes biochemical pathways for producing pimelic acid, 7-aminoheptanoic acid, 7-hydroxyheptanoic acid, heptamethylenediamine or 1,7-heptanediol by forming two terminal functional groups, comprised of carboxyl, amine or hydroxyl group, in a C7 aliphatic backbone substrate. These pathways, metabolic engineering and cultivation strategies described herein rely on the fatty acid synthesis pathway and oxidative cleavage of long chain acyl-[acp] intermediates by a monooxgenase (e.g., cytochrome P450) such as that encoded by BioI from microorganisms such as Bacillus subtillis.

Abstract: The present application relates to a microorganism of the genus Saccharomyces producing lactic acid and a method for preparing lactic acid using the same. More specifically, the present application relates to a microorganism of the genus Saccharomyces producing lactic acid, wherein the microorganism is modified to weaken or inactivate the activity of pyruvate decarboxylase (PDC) compared to its endogenous activity, to introduce the activity of ATP-citrate lyase (ACL), and to enhance pyruvate biosynthetic pathway compared to its endogenous biosynthetic pathway, and a method for producing lactic acid using the microorganism.

Abstract: The present invention relates to a method for storing gaseous hydrogen, comprising the steps of producing methanoate (formate) through contacting gaseous hydrogen with carbon dioxide in the presence of a hydrogen dependent carbon dioxide reductase (HDCR), and thereby storing of said gaseous hydrogen. The HDCR and/or its complex is preferably derived from Acetobacterium woodii.

Abstract: A Labyrinthulid microorganism capable of producing a PUFA only through the elongase-desaturase pathway. A Labyrinthulid microorganism which has no ability of producing a PUFA through the endogenous PUFA-PKS pathway or has the ability at an extremely weak level and which has an ability of producing a PUFA through the endogenous elongase-desaturase pathway. The Labyrinthulid microorganism is a microorganism belonging to the genus Parietichytrium or Parietichytrium.

Abstract: In an aspect, the disclosure provides methods for making neurotransmitters in a host organism. The neurotransmitters can be cannabinoids and derivatives of cannabinoids. The host cells can be microalgae, fungi or other host cells. In a related aspect, the disclosure provides host cells engineered to have biochemical pathways for making neurotransmitters such as cannabinoids.

Abstract: Provided herein, in some embodiments, are systems, methods, and compositions (e.g., cells and cell lysates) for enzymatically converting a polymeric glucose carbohydrate (e.g., starch) to sugar.

Abstract: Provided in the present invention is a method for preparing rebaudioside M by using an enzymatic process, which catalyzes the formation of rebaudioside M using a recombinant Saccharomyces cerevisiae containing a UDP-glucosyltransferase or a UDP-glucosyltransferase prepared therefrom. The recombinant Saccharomyces cerevisiae is obtained by transforming an expression vector containing the UDP-glucosyltransferase gene under the control of a strong promoter.

Abstract: The present invention relates to a method for selectively producing ginsenoside Rd, which is originally present in ginseng in a trace amount, from panaxadiol-type saponins of ginseng, and more specifically to a method capable of obtaining a desired target compound, that is, ginsenoside Rd, in high yields, by treating a panaxadiol-type saponin obtained from ginseng, with particular enzymes to structurally convert the saponins.

Abstract: A method of detecting Listeria monocytogenes. The method comprises providing a culture device with a selective culture medium and a detection article comprising a first indicator system. The selective culture medium facilitates the growth of Listeria microorganisms. When a Listeria microorganism is detected in a sample contacted with the culture medium, the detection article is contacted with the culture medium to detect Listeria monocytogenes.

Abstract: A system and method for managing power in virtualized computer systems are disclosed. In accordance with one embodiment, a request to instantiate a virtual machine is received. A processor determines whether a power state is to be altered to instantiate the virtual machine on a computing system, and in response to the determination, alters the power state.

Abstract: Disclosed is a method for screening for an antimicrobial agent capable of controlling microorganisms generating offensive odor in an air conditioning apparatus. Further disclosed is a method for removing offensive odor in the air conditioning apparatus. The microorganism causing offensive odor in the air conditioning apparatus may be used in the development of a novel antimicrobial agent or in the development of an aromatic for blocking offensive odor by establishing the chemical properties of metabolites of the microorganisms. In addition, there are various industrial applications, for example, by fundamentally removing the cause of offensive odor by creating an environment in which the microorganisms cannot live in the air conditioning apparatus in advance.

Abstract: A microfluidic device comprises a substrate transparent for imaging and having a plurality of spatially defined and separated cell channels having a dimension to accommodate cells in monolayer. A respective first end of the cell channels is in fluid connection with a flow input channel having a first end in fluid connection with a first fluid port and a second end in fluid connection with a second fluid port. A respective second end of the cell channels is in fluid connection with a first end of a respective wash channel having a second end in fluid connection with a flow output channel. The flow output channel is in fluid connection with a third fluid port. The wash channels have a dimension too small to accommodate the cells.

Abstract: A method for reducing a tetrazolium salt.

Abstract: The invention provides a kit for Polymerase Chain Reaction (PCR), comprising a vessel and at least two set of reagents disposed separately in the vessel, wherein each of the at least two set of reagents comprise at least one component selected from the group consisting of a DNA polymerase, nucleoside triphosphates, reaction buffer, and salt, and provided that each set of the at least two set of reagents is different from each other and combination of each of the at least two set of reagents comprises a DNA polymerase, nucleoside triphosphates, reaction buffer, and salt required for performing PCR.

Abstract: Provided herein is technology relating to the manipulation and detection of nucleic acids, including but not limited to compositions, methods, and kits related to nucleotides comprising a chemically reactive linking moiety.